{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:49:05Z","timestamp":1793774945228,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008140","name":"Hans and Nora Buchards Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008140","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["AG075227"],"award-info":[{"award-number":["AG075227"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG075227"],"award-info":[{"award-number":["AG075227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bone.2025.117660","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:58:53Z","timestamp":1758711533000},"page":"117660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study"],"prefix":"10.1016","volume":"201","author":[{"given":"Mette B\u00f8egh","family":"Levring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Diaz-delCastillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Tveden","family":"Gundesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriane","family":"C\u00e9dile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Walther","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Lerberg","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Elisabeth H\u00f8jsgaard","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Just","family":"Vinholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Thor","family":"Asmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Bruun","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustapha","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Levin","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bone.2025.117660_bb0005","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells","volume":"148","author":"Andersen","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2025.117660_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.bone.2025.117660_bb0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2025.117660_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcdb.2020.10.006","article-title":"Multiple myeloma-a painful disease of the bone marrow","volume":"112","author":"Diaz-delCastillo","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.bone.2025.117660_bb0040","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bone.2025.117660_bb0045","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0050","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.bone.2025.117660_bb0055","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2025.117660_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bone.2025.117660_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2007.12.006","article-title":"Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma","volume":"42","author":"Qiang","year":"2008","journal-title":"Bone"},{"issue":"23","key":"10.1016\/j.bone.2025.117660_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235585","article-title":"Novel developments in the treatment of multiple myeloma-associated bone disease","volume":"15","author":"Johansen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bone.2025.117660_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115850","article-title":"Bisphosphonates impair the onset of bone formation at remodeling sites","volume":"145","author":"Jensen","year":"2021","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2025.117660_bb0090","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117660_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101100","article-title":"Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma","volume":"61","author":"Kegyes","year":"2023","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.bone.2025.117660_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.bone.2025.117660_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.bone.2025.117660_bb0115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2010.01485.x","article-title":"First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro","volume":"85","author":"Lund","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.bone.2025.117660_bb0125","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease","volume":"20","author":"Garcia-Gomez","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0135","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12185-023-03601-2","article-title":"Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors","volume":"118","author":"Nakaue","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"17","key":"10.1016\/j.bone.2025.117660_bb0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2025.117660_bb0150","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000940","article-title":"Ixazomib-thalidomide-dexamethasone induction followed by Ixazomib or placebo maintenance in nontransplant eligible newly diagnosed multiple myeloma patients: long-term results of HOVON-126\/NMSG 21.13","volume":"7","author":"Groen","year":"2023","journal-title":"Hemasphere"},{"issue":"10168","key":"10.1016\/j.bone.2025.117660_bb0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020323","article-title":"Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells","volume":"12","author":"Tibullo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bone.2025.117660_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.4807","article-title":"Increased bone volume by Ixazomib in multiple myeloma: 3-month results from an open label phase 2 study","volume":"38","author":"Diaz-delCastillo","year":"2023","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2025.117660_bb0170","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bone.2025.117660_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116399","article-title":"2D size of trabecular bone structure units (BSU) correlate more strongly with 3D architectural parameters than age in human vertebrae","volume":"160","author":"Lamarche","year":"2022","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13287-021-02338-1","article-title":"Identification of a clinical signature predictive of differentiation fate of human bone marrow stromal cells","volume":"12","author":"Kowal","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.bone.2025.117660_bb0185","article-title":"Serum levels of bone turnover markers including calculation of Z-scores: data from a Dutch healthy reference cohort","volume":"19","author":"Siderius","year":"2023","journal-title":"Bone Rep."},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpet.2022.09.001","article-title":"Emerging role of (18)F-NaF PET\/computed tomographic imaging in osteoporosis: a potential upgrade to the osteoporosis toolbox","volume":"18","author":"Sheppard","year":"2023","journal-title":"PET Clin."},{"issue":"3","key":"10.1016\/j.bone.2025.117660_bb0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cpet.2019.03.004","article-title":"Evolving roles of fluorodeoxyglucose and sodium fluoride in assessment of multiple Myeloma patients: introducing a novel method of PET quantification to overcome shortcomings of the existing approaches","volume":"14","author":"Zadeh","year":"2019","journal-title":"PET Clin."},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0205","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.15095","article-title":"Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma","volume":"184","author":"Hildebrandt","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bone.2025.117660_bb0210","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0215","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells","volume":"148","author":"Andersen","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bone.2025.117660_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cpet.2012.04.001","article-title":"Quantitative PET imaging using (18)F sodium fluoride in the assessment of metabolic bone diseases and the monitoring of their response to therapy","volume":"7","author":"Blake","year":"2012","journal-title":"PET Clin."},{"issue":"12","key":"10.1016\/j.bone.2025.117660_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126504","article-title":"(18)F-sodium fluoride PET as a diagnostic modality for metabolic, autoimmune, and osteogenic bone disorders: cellular mechanisms and clinical applications","volume":"22","author":"Park","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2025.117660_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115267","article-title":"Correlation between (18)F-sodium fluoride positron emission tomography and bone histomorphometry in dialysis patients","volume":"134","author":"Aaltonen","year":"2020","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2025.117660_bb0235","doi-asserted-by":"crossref","first-page":"14930","DOI":"10.1096\/fj.202001340R","article-title":"Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation","volume":"34","author":"Hoshikawa","year":"2020","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bone.2025.117660_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061257","article-title":"Carfilzomib improves bone metabolism in patients with advanced relapsed\/refractory multiple myeloma: results of the CarMMa study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bone.2025.117660_bb0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ejh.13709","article-title":"Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group","volume":"108","author":"Gregersen","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.bone.2025.117660_bb0250","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ajh.25415","article-title":"Progression with clinical features is associated with worse subsequent survival in multiple myeloma","volume":"94","author":"Chakraborty","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.bone.2025.117660_bb0255","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garcia-Sanz","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bone.2025.117660_bb0260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jcp.21787","article-title":"Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades","volume":"220","author":"Ang","year":"2009","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.bone.2025.117660_bb0265","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:00:17Z","timestamp":1780300817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225002728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S8756328225002728"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117660","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117660"}}